Please assess the completion status of the following clinical trial:

Trial Title: Efficacy and Safety Study of Apremilast in Subjects With Moderate to Severe Atopic Dermatitis

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Inclusion Criteria:~1. Males or females, aged ≥ 18 years (≥ 20 for Japanese subjects) at the time of consent.~2. Have a diagnosis of atopic dermatitis for ≥ 12 months.~3. Have moderate to severe atopic dermatitis which is considered inappropriate for topical therapy or which cannot be adequately controlled by topical therapy.~4. Meet the laboratory criteria as defined per protocol~5. Females of Childbearing Potential (FCBP) must have a negative pregnancy test at Screening and Baseline. Sexually active FCBP must use one of the approved contraceptive options required per protocol while on and for at least 28 days after the last dose of study medication~6. Male subjects (including those who have had a vasectomy) who engage in activity in which conception is possible must use barrier contraception while on and for at least 28 days after the last dose of study medication.~Exclusion Criteria:~1. Active tuberculosis (TB) or a history of inadequately treated tuberculosis.~2. Positive for hepatitis B surface antigen or hepatitis C antibody~3. Pregnant or breast feeding~4. History of allergy to any component of the study medication.~5. Active skin infection requiring systemic antimicrobials at Baseline.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Apremilast 40 mg (Type: EXPERIMENTAL): Apremilast 40 mg administered orally twice daily (BID) for 12 weeks (following dose titration) during the placebo controlled phase followed by 40 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
- Apremilast 30 mg (Type: EXPERIMENTAL): Apremilast 30 mg administered orally BID for 12 weeks (following dose titration) during the placebo controlled phase followed by 30 mg Apremilast tablets orally administered BID for an additional 12 weeks in the active treatment phase
- Placebo + Apremilast 40 mg (Type: EXPERIMENTAL): Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 40 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
- Placebo + Apremilast 30 mg (Type: EXPERIMENTAL): Placebo administered orally BID for 12 weeks, during the placebo controlled phase followed by 30 mg Apremilast tablets orally BID for an additional 12 weeks in the active treatment phase
- Placebo (Type: PLACEBO_COMPARATOR): Oral Placebo tablets administered twice daily (BID) for 12 weeks during the placebo-controlled phase.

Based on this trial design, predict the completion outcome and termination type (if applicable).